Janssen Search
Search results
Oral Cavity and Oropharyngeal /Cervical Cancer
Article Block Text: Diagnosing pre-cancer early to intercept disease with precision solutions. Article Type: Disease Interception Accelerator Oral Cavity & Oropharyngeal Cancer/Cervical Cancer Developing risk-assessment processes, diagnostics and ...
The Resilience of Cancer Research
ESMO 2020: The Resilience of Cancer Research Each fall, I look forward to the European Society for Medical Oncology (ESMO) Annual Congress and the chance to connect with colleagues and peers from around the globe to engage in important scientific exchange ...
Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer
Apr 30, 2023 United States Study results of novel drug-eluting technology highlight potential durability of TAR-200 in patient population with high unmet need CHICAGO, April 30, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson ...
Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Erdafitinib for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer with Susceptible FGFR Alterations
Sep 08, 2023 Belgium Pending approval, erdafitinib, an investigational, once-daily oral pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, [1] will become the first therapy targeting FGFR alterations [2] in patients with metastatic ...
Mark Erion, Ph.D.
MARK ERION, PH.D. GLOBAL VICE PRESIDENT AND INTERNAL & EXTERNAL DISCOVERY HEAD CARDIOVASCULAR AND METABOLISM Mark Erion, Ph.D., is Global Vice President and Internal & External Discovery Head of Cardiovascular and Metabolism. Mark manages a team ...
ASCO 2023
Welcome to the Janssen Oncology Virtual Newsroom Peter Lebowitz, M.D., Ph.D. Global Therapeutic Area Head Oncology Janssen Research & Development, LLC Tyrone Brewer U.S. President Oncology Janssen Biotech, Inc. Latest News Janssen Highlights ...
Suicide: The Public Health Crisis We Need to Discuss
Suicide: The Public Health Crisis We Need to Discuss Tragically, a suicide takes place every 40 seconds, claiming more than 800,000 lives each year globally. 1 In the United States alone, in 2016 nearly 45,000 Americans age 10 or older died by suicide. ...
Late-breaking results show nipocalimab significantly improves Sjögren’s disease activity in a Phase 2 study
Jun 15, 2024 Patients who received nipocalimab 15 mg/kg demonstrated a greater than 70 percent relative average improvement on the primary endpoint compared to patients who received placebo Sjögren’s disease is a chronic, debilitating, and prevalent ...
Building a Better Tomorrow for All
Building a Better Tomorrow for All For decades, vaccines have had an unparalleled impact on global public health and remain one of the most effective methods of preventing infectious diseases worldwide. This year, the World Health Organization (WHO) ...
TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non–muscle-invasive bladder cancer
May 03, 2024 New data from Phase 2b SunRISe-1 study show rapid achievement of complete response (CR) with 98% achieving a CR within 12 weeks TAR-200 provides durable CRs in patients with Bacillus Calmette-Guérin (BCG) – unresponsive high-risk non – muscle ...